KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EPS (Weighted Average and Diluted) (2020 - 2026)

Palvella Therapeutics has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$0.14 for Q2 2022.

  • Quarterly EPS (Weighted Average and Diluted) rose 44.0% to -$0.14 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was -$0.58 through Jun 2022, up 30.95% year-over-year, with the annual reading at -$3.71 for FY2025, 52.62% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.14 for Q2 2022 at Palvella Therapeutics, down from -$0.07 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.07 in Q1 2021 and troughed at -$0.26 in Q4 2020.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.14 (2022), against an average of -$0.17.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 50.0% in 2021 against a maximum downside of 177.78% in 2021.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.26 in 2020, then surged by 50.0% to -$0.13 in 2021, then dropped by 7.69% to -$0.14 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's EPS (Weighted Average and Diluted) are -$0.14 (Q2 2022), -$0.07 (Q1 2022), and -$0.13 (Q4 2021).